This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
EASL International Consensus Conference on Hepatitis B: 13–14 September, 2002, Geneva, Switzerland: consensus statement (long version). J Hepatol 2003; 39 Suppl 1: S3–S25
Hadziyannis SJ et al. (2000) Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen negative chronic hepatitis B. Hepatology 32: 847–851
Papatheodoridis GV et al. (2001) The long term outcome of interferon alfa treated and untreated patients with HBe-antigen negative chronic hepatitis. J Hepatol 34: 306–313
Schalm SW et al. (2000) Lamivudine and alfa interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 46: 562–568
Cooksley WGE et al. (2003) Peginterferon alpha 2-a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10: 298–305
Acknowledgements
The synopsis was written by Minal Chande, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
GC has participated in trials sponsored by Roche, Schering-Plough, GlaxoSmithKline, Gilead, Bristol Myers Squibb. He has served on advisory boards for Roche and GlaxoSmithKline.
Glossary
- Hepatitis B e ANTIGEN (HBeAg)-NEGATIVE CHRONIC HEPATITIS B
-
The result of a mutation in the precore or core promoter region of hepatitis B
Rights and permissions
About this article
Cite this article
Cooksley, G. Does the addition of lamivudine to peginterferon α-2a sustain response rates in HBeAg-negative hepatitis B?. Nat Rev Gastroenterol Hepatol 2, 12–13 (2005). https://doi.org/10.1038/ncpgasthep0068
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0068